NeuroSense Therapeutics Ltd. Ordinary Shares
NRSNNeuroSense Therapeutics Ltd. is a biotechnology company focused on developing therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's. The company leverages its proprietary platform to identify and advance drugs aimed at addressing the underlying causes of these disorders. Founded to translate scientific discoveries into innovative treatments, NeuroSense aims to improve patient outcomes through targeted neuroprotective and disease-modifying therapies.
Company News
The article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. AeroVironment posted adjusted earnings of 97 cents per shares, beating analysts’ estimates of 62 cents per share. The company’s revenue came in at $180.8 million beating estimates of $170.908 million. AeroVironment shares di...
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28% to 14,270.30. The S&P 500 also rose, gaining, 0.32% to 4,581.88. Check This Out: Top 3 Materials Stocks That Are Set To Fly In Q4 Â Leading and L...
Shares of SentinelOne, Inc. (NYSE: S) rose sharply in pre-market trading after the company reported stronger-than-expected results for its third quarter and raised its annual revenue outlook. SentinelOne reported third-quarter revenue of $164.2 million, beating the analyst consensus estimate of $156.09 million. The company also reported an adjus...
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Daktronics posted quarterly earnings of 5 cents per share, missing market estimates of 13 cents per share. The company’s quarterly sales came in at $199.37 million versus expectations of $213.70 million, according to Benzinga Pro. ...
